1

Reactivation of an errantivirus in *Drosophila* ovarian somatic tissue: from

germline invasion to taming

Marianne Yoth[1], Stéphanie Maupetit-Méhouas[1], Abdou Akkouche[1], Nathalie Gueguen[1],

Benjamin Bertin[2], Silke Jensen[1]*, Emilie Brasset[1]*

[1] iGReD, Université Clermont Auvergne, CNRS, INSERM, Faculté de Médecine, 63000

Clermont-Ferrand, France.

[2] LIMAGRAIN EUROPE, Centre de recherche, 63720 Chappes, France.

* Correspondence: emilie.brasset@uca.fr, silke.jensen@uca.fr

Summary

Most Drosophila transposable elements (TEs) are LTR retrotransposons, some of which belong to the genus Errantivirus and share structural and functional characteristics with vertebrate endogenous retroviruses (ERVs). These virus-derived elements occupy a large part of the genome, but it is unclear whether and how they can be reactivated and if they retain their replication capacity. We created conditions where control of the Drosophila *ZAM* errantivirus through the piRNA pathway was abolished leading to its reactivation in real time in somatic gonadal cells. We show that ZAM may remain active in these cells indicating that errantiviruses may hide from the efficient germline piRNA pathway by being expressed exclusively in somatic cells. After reactivation, *ZAM* invaded the oocytes and severe fertility defects were observed. The germline then set up its own adaptive genomic immune response against the constantly invading errantivirus, restricting invasion and restoring fertility. Our results not only highlight how errantiviruses and their host adapt to each other but also reveal a time window during oogenesis that may be favourable for viral germline invasion and endogenization.

Introduction

In vertebrates, many LTR retrotransposons belong to the family of endogenous retroviruses (ERVs). ERVs are a class of transposable elements (TEs) that are closely related to infectious retroviruses. Retroviruses are a family of RNA viruses defined by their ability to reverse transcribe their RNA genome into DNA which is then integrated into the host cell genome. While most retroviruses infect somatic cells, occasionally they may infect germ cells and if integrated in the germline genome, they may emerge as ERVs: they become permanent elements in the host genome and are vertically transmitted. ERVs are then capable of replicating themselves and integrating at new genomic loci, which contributes to their success in invading vertebrate genomes. In Human, ERV-related sequences occupy 9% of the genome, in mice 12%, in rat 10.2%, in microbats 5.3%, in marmosets 7.5% (http://repeatmasker.org/genomicDatasets/RMGenomicDatasets.html). Each new ERV copy then evolves independently and can be at the origin of the emergence of a new TE family. In mice, IAPE and IAP ERVs illustrate the evolutionary history of ERVs [1]. Indeed, IAPEs are still retroviruses capable of infecting other cells, after an extracellular passage, whereas the highly repeated IAPs, derived from IAPEs by losing the envelope gene (env), are strictly intracellular, evolving within a single cell.

It is crucial to note that TEs, can only be maintained in a species if they are able to transpose into the germline genome. If they do not, at least from time to time, they will accumulate mutations until there are no functional copies left and the TE family dies out. Some TEs gained cell and developmental stage specific expression [2–6]. TEs that have acquired the capacity to be expressed exclusively in somatic cells must therefore maintain their ability to invade germ cells to survive.

ERVs are TEs, and although the presence of TEs in the genome has been shown to provide some evolutionary benefits (reviewed in [7]), unregulated TE expression and transposition represent a threat to genome integrity and host fitness. Thus, under physiological conditions, most TEs are repressed by epigenetic mechanisms and maintained in a dormant state. In metazoan gonads, TE expression and mobilization is restrained by PIWI-interacting RNAs (piRNAs) (reviewed in [8,9]). The piRNA pathway has been extensively studied in the *Drosophila melanogaster* ovary that comprises about 16 ovarioles, each of which contains a succession of follicles composed of germ cells surrounded by somatic follicle cells [10] . piRNAs originate from specific source loci, the piRNA clusters [11]. In Drosophila, the piRNA clusters

expressed in the germline are particularly numerous and diverse while there is only one major piRNA cluster expressed in gonadal somatic cells, that is *flamenco* (*flam*) [12–16].

Within the Drosophila genome, there is a specific group of TEs that share structural and functional characteristics with vertebrate ERVs. These insect LTR transposons are classified as errantiviruses and belong to the Metaviridae family. In *Drosophila melanogaster* some errantiviruses have been shown to have the capacity to move from cell to cell. These include TEs such as *ZAM, Idefix* or *Gypsy* whose expression is restricted to the somatic follicle cells of the ovary [17–24]. The intercellular invasion capacity may pose a particular threat, especially if they are able to cross the so-called Weismann barrier separating somatic and germ cells (reviewed in [25]). In the germ cells, TE expression and transposition are known to be controlled by the piRNA pathway, but research has primarily concentrated on how piRNAs silence TEs that are expressed in the cells where the corresponding piRNAs are produced. The role of piRNAs in the silencing of a TE that is activated in a cell type different from the one where the silencing mechanism must take place remains unclear. Consequently, whether these TEs can escape the robust epigenetic control mediated by piRNAs when arriving in the germline and how they are tamed by the host over time remained to be puzzled out.

The *ZAM* errantivirus was discovered through its uncontrolled activity in an unstable line, RevI-H2, about 25 years ago [26,27]. *ZAM* has 3 intact ORFs encoding proteins whose function is analogous to that of the Gag, Pol and Env proteins of ERVs or retroviruses [26]. In the RevI-H2 Drosophila line bearing a large deletion in the *flamenco* piRNA cluster, *ZAM* had become active and is specifically expressed in gonadal somatic cells [14,17]. Moreover, *ZAM* inserted into multiple new loci in the RevI-H2 line, including a germline-specific piRNA cluster, resulting in unexpected production of germline piRNAs that map to *ZAM* [26–28]. The biological role of these germline *ZAM*-mapping piRNAs remained unexplored.

Since these studies, *ZAM* has emerged as a key model for studying host-TE interactions and the relationship between somatic cells and the germline during TE invasion.

By analyzing different conditions of *ZAM* reactivation, we aimed here to study what happens in real time when an errantivirus is reactivated *de novo* and how the host responds. Specifically, we sought to elucidate whether piRNAs produced in the germline counteract TE invasion from the somatic cells or whether TE transcripts are protected from degradation by virus-like particles when arriving in the germline.

We show that in the RevI-H2 line, *ZAM* is still expressed in the follicle cells but it doesn't

invade the germline while *ZAM* copies with invasive capacities have been maintained in the

genome. To recreate the initial unstable condition, we *de novo* reactivated *ZAM* in the ovarian

follicle cells, either by soma-specific knock-down of the piRNA pathway, or by deleting a *ZAM*

copy in the somatic *flamenco* piRNA cluster, while keeping the piRNA pathway fully

functional. *De novo ZAM* reactivation in the follicle cells led to a massive *ZAM* invasion deep

into the adjacent oocyte and its ooplasm. We demonstrate that this invasion could be impeded

by the expression of *de novo ZAM*-targeting piRNAs produced in the germ cells themselves

demonstrating that these piRNAs are functional against the native *ZAM*. These results show

that by being expressed exclusively in somatic cells, errantiviruses may evade the control by

the very efficient germinal piRNA pathway and remain active for long periods of time. The

challenged germ cells then mount an adaptive genomic immune response to tackle the

permanent invasion.

Results

In an ancient *flamenco* mutant line, ZAM is still expressed, but the line is nevertheless

stable.

To investigate the history of *ZAM* transposition dynamics, we monitored *ZAM* copies in the

RevI-H2i2 line, an isogenic line that was recently derived from the parental flam mutant RevI-

H2 line that has more than 25 years of laboratory history. It had previously been reported that

the RevI-H2 line was unstable and that *ZAM* actively transposed in this line [27]. The *ZAM*

instability in RevI-H2 had been linked to a deletion of a large part of the *flam* piRNA cluster.

This deletion spanned over more than 120 kb and comprised many different TE relics, including

more or less recent copies, and all *ZAM*-related copies of the *flam* locus [14,15].

In the RevI-H2i2 genome, Oxford Nanopore Technology (ONT) genome sequencing revealed

18 *ZAM* copies (Fig. 1a and Table 1 for coordinates). Only one of these *ZAM* copies was also

present in the reference genome (http://flybase.org). The other 17 new insertions were very

similar to the *ZAM* reference element identified in the initial RevI-H2 line [26] and we could

clearly localize 14 of the 17 new *ZAM* insertions. Interestingly, ONT long-read sequencing,

allowed identifying different *ZAM* variants. Specifically, six were full-length *ZAM* elements

(ZAM-fl), one, named *ZAM-v1,* harbored a deleted 5'-UTR (5' untranslated region), two, named

ZAM-v3, had a 303 bp deletion within the 5'-UTR, four had large internal deletions in the

coding regions, and four were full-length insertions with a deletion at the C-terminal end of the

pol gene of positions 5494 to 6120 in the *ZAM* internal sequence [26] (Repbase *ZAM*_I,

https://www.girinst.org/repbase/[29]). This deleted part of the *pol* gene does not correspond to

any known protein domain and the fact that there are five identical copies of this *ZAM* at

different locations in the RevI-H2i2 genome indicates that this *ZAM* variant, which we named

ZAM-v2, is competent for transposition. The full-length *ZAM*, *ZAM-v1* and *ZAM-v3* copies all

potentially encode Gag, Pol and Env proteins (Fig. 1a).

In the initial RevI-H2 line, a *ZAM* insertion was found in the germline piRNA cluster *9*, which

is close to the X chromosome centromere [28]. Here, in the RevI-H2i2 line, thanks to long-read

sequencing, we could identify *ZAM* insertions in repeated sequences, such as piRNA clusters,

more accurately. We now identified three *ZAM* insertions in piRNA cluster *9* (one *ZAM-fl* and

two *ZAM-v2*), and also a *ZAM-fl* insertion, which is localized in either piRNA cluster *13* or

cluster *56* (uncertainty is due to flanking repeats, piRNA clusters as in [30]) (Fig. 1a). We

reanalyzed the Illumina sequencing data of the initial RevI-H2 line and found evidence that all

these *ZAM* insertions in piRNA cluster 9 and 13 or 56 were already present ten years ago, and

that at least 14 of the *ZAM* insertions in the RevI-H2i2 line were already present in the parental

RevI-H2 line. This result indicates that the genomic *ZAM* profile is the same as ten years ago

and suggests that no new *ZAM* insertions occurred since then in the germline.

Strikingly, no new *ZAM* insertion was detected in the *flam* piRNA cluster. Thus, in the RevI-

H2i2 line, no *ZAM* piRNA can be produced from *flam*, the major somatic piRNA source locus.

Interestingly, single-molecule RNA fluorescence *in situ* hybridization (smRNA FISH) revealed

the presence of *ZAM* RNA in RevI-H2i2 follicle cells, demonstrating that *ZAM* is not silenced

in these somatic cells and that transcriptionally active copies of *ZAM* are still present in the

genome. *ZAM* transcripts were produced in follicle cells, starting very early during oogenesis

in the germarium. Then, after stage 8, *ZAM* transcripts accumulated in a patch of follicle cells

located at the posterior side of the follicles. We did not detect any *ZAM* staining in germ cells

(nurse cells or oocytes) (Fig. 1b). RNase A treatment led to complete loss of *ZAM* staining in

the follicle cells (Supplementary Fig. 1a). We did not detect any *ZAM* RNA in the Iso1A, w^{1118}

and w^{IR6} control ovaries (Supplementary Fig. 1b). Using RT-qPCR, we confirmed that *ZAM*

was expressed in the RevI-H2i2 ovaries. Conversely, other TEs such as the soma-specific *Gypsy*

and the germline-specific *Burdock*, were not upregulated (Fig. 1c). Interestingly, we observed

that, besides the full-length ZAM, at least *ZAM* variants ZAM-v2 and ZAM-v3 are expressed

in RevI-H2i2 ovaries (Supplementary Fig. 1c,d). *ZAM* is an errantivirus that encodes Gag, Pol

and Env proteins. Using immunostaining, we were able to detect *ZAM* Gag and Env proteins

that accumulated in the posterior follicle cells in late-stage follicles (> stage 9) (Fig. 1d). All

these results showed that *ZAM* transcripts and proteins are still expressed in the RevI-H2i2 line.

Although *ZAM* was expressed in follicle cells, the RevI-H2i2 line was fertile. Indeed, the ovary

morphology and the number of eggs laid were comparable in RevI-H2i2 and control females

(Fig. 1e, f). Altogether, these results indicate that no silencing mechanism had been set up to

repress the *ZAM* errantivirus in follicle cells suggesting that *ZAM* expression has no major

deleterious effect in the RevI-H2i2 line and that there is no selective pressure to specifically

repress *ZAM* in the follicles cells. These findings suggest that RevI-H2i2 is a stable line

although *ZAM* is actively expressed in follicle cells.

Germline *ZAM*-targeting piRNAs constrain *ZAM* invasion from adjacent somatic cells.

Transposition of *ZAM* in the initial RevI-H2 line had occurred in the germline, as attested by

the transmission of *ZAM* insertions to the offspring, despite the fact that *ZAM* is specifically

and exclusively expressed in the somatic follicle cells. This confirms that the *ZAM* errantivirus,

when expressed in follicle cells, transits to the germline to integrate into the germ cell genome.

However, we showed that *ZAM* insertions are stabilized in the RevI-H2i2 line. The RevI-H2i2

flies produce high amounts of sense and antisense *ZAM*-derived piRNAs with a ping-pong

signature, revealed by an over-representation of 10-nucleotide 5'-overlaps between sense and

antisense *ZAM*-derived piRNAs (Fig. 2a), while there was no ping-pong signature for ZAM in

diverse control lines [23,28]. Ping-pong amplification of piRNAs can only occur in the germline

in Drosophila (reviewed in [31]). Thus, these *ZAM* piRNAs observed in RevI-H2i2 are derived

from the germline. Importantly, our previous research has demonstrated that the X chromosome

of the RevI-H2 line, which contains the *ZAM* copies inserted in germline piRNA clusters, is

both necessary and sufficient to produce *ZAM*-regulating piRNAs [28]. Additionally, in both

RevI-H2 [28] and RevI-H2i2 background, a *ZAM* sensor transgene is silenced in the germ cells

(Supplementary Fig. 2a). We therefore hypothesized that piRNAs produced in germ cells can

thwart *ZAM* invasion from somatic cells to the germline and thus protect the germline from new

ZAM transposition. However, piRNAs are known to silence TEs in the cells where they are

produced and TEs, such as *ZAM*, are not expressed directly in germ cells but arrive from

surrounding somatic cells. Moreover, *ZAM* RNA may transit in an encapsulated form and the

capacity of piRNAs to target encapsulated RNAs remains unknown.

To test whether germline ZAM-derived piRNAs were efficient to counteract an invasion

coming from surrounding somatic cells, we abolished the piRNA pathway in the germ cells by

germline-specific knock-down (GLKD) of piRNA pathway components, in a RevI-H2i2

genetic background producing *ZAM* piRNAs in the germline. It is important to note that, during

the genetic crosses performed, only the X chromosome of the RevI-H2i2 was tracked to ensure

that the ZAM insertions in the germline piRNA clusters were maintained (crossing schemes

presented in Figure S6). We observed that the germline knock-down of proteins of the piRNA

pathway, Zucchini (Zuc), Argonaute 3 (Ago3) and Piwi, led to a decrease in the production of

ZAM-targeting piRNAs, i.e. piRNAs that are complementary and thus antisense to ZAM (Fig.

2b, Supplementary Fig.2b). The decrease in antisense piRNAs was comparable to that observed

for germline TEs (i.e., *Burdock* and *Accord*) or intermediate TEs (i.e., *Idefix*), while somatic-

TEs such as *Tirant* did not show a similar decrease. Furthermore, in *ago3*-GLKD ovaries, the

ping-pong signature for *ZAM* was abolished, as for many other germline-specific TEs, while it

was maintained in *piwi*-GLKD ovaries for instance (Fig. 2c, Supplementary Fig. 2c).

We then analyzed the subcellular localization of *ZAM* RNAs by smRNA FISH in the RevI-

H2i2 *white*-GLKD control line in which *ZAM*-derived piRNAs are produced in the germline.

ZAM RNA staining was restricted to follicle cells, only a minor *ZAM* RNA signal was detected

in the posterior pole of approximately 10% of stage 10 oocytes (Fig. 2d,e). However, when the

piRNA pathway was abolished in RevI-H2i2 germ cells through *vreteno (vret)*, *zuc, ago3* or

armitage (armi) GLKD, ZAM RNA was no longer restricted to follicle cells, a high signal was

also detected in oocytes. *ZAM* RNA spread throughout the ooplasm, but was clearly enriched

at the posterior pole of the oocyte, adjacent to the *ZAM*-expressing follicle cells, supporting the

fact that *ZAM* RNA originated from follicle cells (Fig. 2d). Actually, 30-70% of stage 10

follicles showed a strong *ZAM* RNA signal in oocytes (Fig. 2e). The strongest invasion

phenotype was observed for the RevI-H2i2 *ago3*-GLKD condition where we found a decrease

in the production of *ZAM*-derived piRNAs and the loss of the ping-pong signature (Fig. 2b). In

this condition, *ZAM* RNA accumulation in the ooplasm was correlated with a strong increase

of *ZAM* RNA in total ovaries (RT-qPCR data) (Supplementary Fig. 2d). These results showed

that when the piRNA pathway is affected in the germline, *ZAM* RNAs transit from the somatic

follicle cells, where they are produced, to the oocyte. Altogether, our data strongly suggest that

ZAM piRNAs produced by the germline piRNA pathway trigger post-transcriptional silencing

of *ZAM* RNAs arriving from follicle cells.

We confirmed this finding using a line where no *ZAM*-derived piRNA is produced in the

germline (*w^1118* genetic background) and in which we knocked down the piRNA pathway in the

follicle cells by somatic knock-down (sKD) of *armi*, *vret*, *piwi* or *yb*. The amount of antisense

piRNAs that target soma-specific TEs, including *ZAM,* was strongly decreased (Fig. 2f,

Supplementary Fig. 2e, f). RT-qPCR analysis showed that *ZAM* and another soma-specific TE,

Gypsy, were derepressed, but not the germline-specific *Burdock* (Supplementary Fig. 2g).

Importantly, smRNA FISH results revealed that *ZAM* RNAs were not restricted to the posterior

follicle cells. Like in ovaries harboring GLKD of the piRNA pathway in RevI-H2i2

background, *ZAM* RNAs were present in oocytes (Fig. 2g,h, Supplementary Fig. 2h). We

detected *ZAM* RNAs in the ooplasm in 90% of stage 10 follicles (Fig. 2i). This result confirmed

that, when no *ZAM* piRNA is produced in the germline, *ZAM* RNAs expressed in the somatic

follicle cells transit to the oocyte.

ZAM RNAs transcribed in follicle cells transit to the oocyte and are conveyed to the

embryos in absence of germline ZAM piRNAs.

Although *ZAM* is expected to be transcribed only in follicle cells due to its dependence on the

Pointed somatic transcription factor [17,32], it was possible that some ZAM copies acquired the

capacity to be expressed in the germline over time. Therefore, we wanted to rule out the

possibility that *ZAM* RNAs detected in the RevI-H2i2 oocyte originated from germinal nurse

cells. If some *ZAM* genomic insertions could be expressed in the germline of the RevI-H2i2

line, then germline depletion of *Piwi*, which is required for the transcriptional gene silencing of

TEs, should lead to the transcriptional de-silencing of *ZAM*. We observed that Piwi-GLKD in

the RevI-H2i2 ovaries led to the de-silencing of TEs that are capable of transcribing in the

germline such as *Burdock*. However, we did not observe any changes in either the *ZAM* RNA

level or localization (Fig. 3a,b). Moreover, depletion of *Ago3* induced a substantial

accumulation of *ZAM* RNA solely in the ooplasm. In contrast to TEs expressed in the germline

(e.g, *Burdock*), we never detected *ZAM* RNA staining in the cytoplasm of the nurse cells at any

stage (Fig. 3c). These results strongly support that *ZAM* cannot be expressed in the RevI-H2i2

germ cells and that *ZAM* RNAs detected in oocytes originate from the somatic follicle cells, not

nurse cells.

Throughout the animal kingdom, the first embryonic development stages are controlled by

transcripts and proteins deposited by the mother during oogenesis [33]. In Drosophila, most of the

maternal mRNAs are dumped from nurse cells into the oocyte during oogenesis. Although *ZAM*

transcripts originate from the somatic follicle cells, when we investigated *ZAM* RNA

transmission to the oocyte, we found such transcripts also in early embryos. Indeed, in

conditions where *ZAM* RNA had been detected in oocytes, smRNA FISH experiments revealed

a strong accumulation of *ZAM* RNAs in early embryos, before the zygotic transition, 0-2 hours

after egg laying: from a RevI-H2i2 mother with GLKD of the piRNA pathway, and also from

a mother without germinal *ZAM* piRNAs with sKD of the piRNA pathway in follicle cells (Fig.

3d, Supplementary Fig. 3a). Furthermore, *ZAM* RNAs accumulated at the posterior pole of early

embryos where future germ cells cellularize (Fig. 3e, Supplementary Fig.3b). We detected *ZAM*

RNA in high quantity until stage 5 of embryogenesis and few *ZAM* RNA signal persisting until

the cellularization of the blastoderm (~stage 8-9) (Fig. 3f). In the progeny of the RevI-H2i2

line, we did not detect any *ZAM* RNA, although *ZAM* RNAs were produced in follicle cells of

RevI-H2i2 ovaries (Fig. 3d). This confirmed that *ZAM* invasion of the germline does not occur

in this line. These data revealed an efficient post-transcriptional silencing of *ZAM* RNAs

arriving from follicle cells into the oocyte by piRNAs produced in the germline. This

mechanism should limit the transposition of the somatic *ZAM* retrotransposon into the germline

genome.

***De novo ZAM* reactivation leads to massive oocyte invasion and may result in severe**

fertility defects.

Our results demonstrate that an adaptive response can emerge to counteract the invasion of

germ cells by an errantivirus. To go deeper, we sought to assess the direct impact of reactivating

an errantivirus in real time, before the establishment of any adaptive response by the germline.

To conduct this study, we aimed to specifically reactivate *ZAM de novo*. The loss of the piRNA

pathway in the somatic follicle cells leads to *ZAM* reactivation, however many other TEs are

also desilenced (Supplementary Fig. 2e, g). Moreover, alteration in the expression of piRNA

pathway genes also results in severe developmental defects during oogenesis [34–37]. Therefore,

this model cannot be used to specifically analyze the impact of *ZAM* reactivation in ovaries. On

the other hand, in the RevI-H2 line where *ZAM* was also reactivated, a large deletion of

flamenco occurred during non-targeted mutagenesis and an adaptive response had already been

set up in the germline. Thus, we chose to create a condition where a single TE is reactivated *de*

novo and the piRNA pathway is fully functional.

Using CRISPR-Cas9, we *de novo* deleted the longest *ZAM* copy in the *flam* piRNA cluster in a

line carrying the X chromosome of the Iso1A reference line. As in this line, the *flam ZAM* copy

is at the genomic position X:21,778,810..21,783,994, we used two guides designed to create a

deletion spanning over X:21,777,135..21,784,062 (6926 pb). We named the resulting line

flamΔZAM. Mapping of genome-unique piRNAs to the *flam* locus highlighted the complete

loss of piRNA production in the targeted region compared with the control Iso1A line (Fig. 4a).

Conversely, the global production of genome-unique piRNAs mapping upstream and

downstream of *ZAM* was not affected. We confirmed that the deletion induced a strong decrease

of all piRNAs mapping to the internal regions of the reference *ZAM*. However, piRNAs

targeting the *ZAM* LTR were still produced (Fig. 4b). In line with these results, PCR

amplification and DNA sequencing of the CRISPR-Cas9 target locus showed that only the

internal regions of *ZAM* had been deleted from the *flam* piRNA cluster, resulting in the retention

of a solo-LTR at the initial *ZAM* insertion site (Supplementary Fig. 4).

In the *flamΔZAM line*, only the production of *ZAM*-derived antisense piRNAs was strongly

altered, whereas the production of antisense piRNAs mapping to other TEs was not affected

(Fig. 4c). This shows that the *ZAM* deletion from *flam* impairs *ZAM*-derived piRNA production,

but does not affect the global piRNA production in ovaries. In sum, in the *flamΔZAM* line, the

piRNA pathway was functional and almost no piRNAs that could target the internal *ZAM*

sequences were produced.

We then analyzed *ZAM* RNA expression by smRNA FISH in *flamΔZAM* ovaries. Surprisingly,

we did not detect any *ZAM* expression (Fig. 4d- panel 1). Based on this observation, we

hypothesized that either there was no functional *ZAM* copy in the *flamΔZAM* line, or that the

ZAM solo-LTR retained in *flam* was sufficient to silence *ZAM* expression. To check this, we

exchanged chromosome II or III of the *flamΔZAM* line with chromosome II or III of the RevI-

H2i2 line that each contains three or two recently transposed potentially functional *ZAM* copies,

respectively. We made sure not to introduce the ZAM copies located in germline piRNA

clusters of the X chromosome of the RevI-H2i2 line that are involved in the production of

ZAM-regulating piRNAs in the germline. smRNA FISH revealed that *ZAM* RNAs were

strongly expressed when these *ZAM* copies were added to the genome of the *flamΔZAM* line

(Fig. 4d – panels 2 and 3). We also observed a strong invasion of oocytes with chromosome II,

where approximately 70% of stage 10 follicles presented *ZAM* RNAs in the ooplasm, and

moderate invasion with chromosome III. Similarly, we observed strong invasion of the oocyte

when we added three euchromatic *ZAM* copies located on the telomere side of the X

chromosome of the RevI-H2 line to the *flamΔZAM* genome (Fig. 4d – panel 4). Overall, our

findings show that in the absence of *ZAM*-derived piRNAs in the somatic follicle cells and in

the germline, transcripts from functional *ZAM* copies massively invade the oocytes.

Additionally, our results demonstrate that the presence of a solo-LTR of *ZAM* (454 bp) in the

flam piRNA cluster of the *flamΔZAM* line was not sufficient to silence *ZAM* expression in

follicle cells (Supplementary Fig. 4a). The three *ZAM* copies added to the X chromosome of

the *flamΔZAM* line consist of one full length *ZAM* insertion (*ZAM-fl*), one *ZAM-v2* and one

ZAM-v3. Utilizing the sequence specificity of each insertion, we conducted RT-PCR analysis

to determine which copies were expressed. The results revealed that *ZAM-fl*, *ZAM-v2* and *ZAM-*

v3 copies are expressed in RevI-H2i2 ovaries as well as when joined to the *flamΔZAM* genome

(Supplementary Fig, 4b).

An important observation was that the *flamΔZAM* flies that contain the three functional *ZAM*

copies on the X chromosome displayed atrophied ovaries and reduced fertility compared with

the control *flamΔZAM* flies that lack functional *ZAM* copies (Fig. 4e,f). Specifically, 90% of

flamΔZAM females with active *ZAM* copies did not lay eggs. These data indicate that the

reactivation of one single errantivirus in a patch of follicle cells can induce severe fertility

defects. These results suggest that when *ZAM* piRNAs are produced in the germline, they

contribute to ensure not only genome integrity but also fertility by protecting the oocytes against

ZAM invasion.

No initial small RNA response takes place after *ZAM* reactivation.

The reactivation of an errantivirus, such as *ZAM,* in a genetic context where the piRNA pathway

is functional provides a unique opportunity to examine the genomic immune response to TE

reactivation and germline invasion. piRNAs and siRNAs are the two main classes of small

RNAs produced to control the expression of transposable elements and counteract viral

infection, respectively. Moreover, invading viral RNAs can be processed to small RNAs to

initiate a primary response [38,39]. To characterize the small RNA response upon *ZAM*

reactivation, we sequenced small RNAs that are complexed with Argonaute proteins (named

here "regulatory" piRNAs) from *flamΔZAM* ovaries containing two or four potentially

functional *ZAM* copies. In the *flamΔZAM* line, there were no *de novo ZAM* piRNAs (23 to 29

nt) produced upon *ZAM* reactivation, despite germline invasion. Indeed, only few sense and

antisense *ZAM* piRNAs were detected in the ovaries of the *flamΔZAM* line that contained

functional *ZAM* copies (Fig. 5a, Supplementary Fig. 5a). Moreover, this lack of piRNA

production concerned only *ZAM*. The level of regulatory piRNAs targeting other TEs was not

reduced (Fig. 5b, Supplementary Fig. 5b).

We sequenced total small RNAs in *vret-* or *yb*-sKD ovaries where *ZAM* was also reactivated.

Surprisingly we observed sense *ZAM*-mapping small RNAs of various sizes, including 23-29 nt

small RNAs that are not produced in a *white*-sKD control condition (Supplementary Fig. 5c).

However, the sense 23-29 nt *ZAM*-derived small RNAs detected in *yb*- and *vret*-sKD ovaries

did not display uridine bias at the 5' end, a feature of mature primary piRNAs (Supplementary

Fig. 5d). Furthermore, these sense *ZAM*-mapping small RNAs were not immunoprecipitated

with Piwi proteins. We detected almost no Piwi-bound sense or antisense *ZAM*-mapping

piRNAs in *vret-* or *yb*-sKD ovaries (Supplementary Fig. 5e). In addition, no sense regulatory

ZAM piRNAs complexed with Argonaute proteins were detected in *vret*-sKD ovaries

(Supplementary Fig. 2f). These results suggest that the sense *ZAM*-mapping small RNAs are

most likely degradation products of excess *ZAM* sense transcripts and not piRNAs. Thus, in

these different conditions, we did not detect any primary piRNA response either in the somatic

cells where *ZAM* is expressed or in the oocyte that it invades.

Given that the *ZAM* errantivirus shares some structural and functional characteristics with

retroviruses, we also asked whether *ZAM* reactivation could trigger a siRNA response. For this,

we analyzed the production of 21 nt small RNAs complexed with Argonaute proteins

("regulatory" siRNAs). Similar levels of *ZAM* 21 nt small RNAs were produced in a control

line and in the *flamΔZAM* line with functional *ZAM* copies (Fig. 5c). Globally, the production

of 21 nt small RNAs in this line was comparable to the control for all TEs, including *ZAM* (Fig.

5d). *ZAM*-mapping 21 nt small RNAs were slightly increased only in the *vret*-sKD condition,

compared to the *white*-sKD control line without *ZAM* expression (Supplementary Fig. 5f).

Overall, our results suggest that no or very few siRNAs that could protect ovaries from *ZAM*

activity are produced upon activation of this errantivirus in follicle cells.

Therefore, we propose that no innate small RNA response is triggered in the lines where *ZAM*

is reactivated, suggesting that *ZAM* will not be brought under control until the establishment of

specific adaptive immunity and immune memory.

Discussion

The discovery that piRNAs produced in germ cells not only restrict TE expression in the

germline itself but also counteract the invasion of errantiviruses from adjacent cells reveals a

novel role of piRNAs produced locally as an effective defense mechanism at the tissue scale.

When piRNAs against *ZAM* are produced in the germline, *ZAM* transcripts are limited to a patch

of follicle cells and flies are fertile. Conversely, in the absence of *ZAM*-derived piRNAs in the

germline, transcripts from functional *ZAM* copies massively invade the oocytes and are even

transmitted to the embryos. At the molecular level, our study revealed that piRNAs produced

in nurse cells and dumped into the oocyte can target RNAs produced by follicle cells and

delivered to the oocyte. It is tempting to speculate that the *ZAM* RNAs arriving from somatic

cells are targeted by complementary antisense piRNAs and degraded through the ping-pong cycle (reviewed in [31]). This would result in the production of *ZAM* sense piRNAs, thus participating in the amplification of the pool of piRNAs against *ZAM* and strengthening the defense mechanism against the invasion.

Transposition in the germ cell genome is crucial for TE propagation in a population because it allows the vertical transmission of new insertions. At the time of invasion (e.g. in the *flamΔZAM* line), no *ZAM*-derived piRNA was produced in somatic or germ cells. Therefore, this condition could be compared to what happens when a TE first enters a new species by horizontal transfer. In this case, according to several studies, an initial transposition burst occurs that leads to TE accumulation in the genome before the induction of an adaptive response by the host to control transposition [40–45]. We found at least 17 new *ZAM* insertions in the RevI-H2i2 genome, testifying that *ZAM* actively transposed. Surprisingly, we identified three *ZAM* insertions in the same germline piRNA cluster on the X chromosome. It has been proposed that two different mechanisms can explain the *de novo* piRNA production required to specifically silence a novel invading TE. Indeed, piRNAs can be produced from a new TE insertion into a pre-existing piRNA cluster, and also by stand-alone TE insertions converted into piRNA-producing loci [46–49]. Interestingly, when active *ZAM* copies are added into a *flamΔZAM* genetic background, these copies do not produce regulatory *ZAM*-derived piRNAs and are not converted into piRNA producing regions. Actually, *ZAM* should be transcriptionally inactive in the germline because *ZAM* expression is regulated by the somatic transcription factor Pointed [32]. Therefore, although the contribution of individual copies needs to be investigated, our data strongly suggest that germline *ZAM* piRNAs originate at least in part from piRNA clusters. In line with our findings, computer simulations of the TE invasion dynamics suggested that several insertions in piRNA clusters are likely to be required to stop the invasion in the germline [50]. Conversely, we found that a single insertion in a somatic piRNA cluster, such as *flamenco,* is sufficient for TE

silencing in the somatic follicle cells, as previously suggested [14]. Indeed, we show here that in

follicle cells, the *flamenco* piRNA cluster acts alone as the principal regulator of transposon

activity. A precise deletion of the internal part of the *ZAM* TE inserted in *flamenco* leads to

complete derepression of functional *ZAM* copies. Surprisingly, it seems that reactivation of this

errantivirus in only a patch of somatic cells can lead to severe fertility defects. However, in the

germline, the deletion of the three most highly expressed germline piRNA clusters (42AB, 38C,

and 20A) affected neither fertility nor TE silencing [48]. This could be explained by the fact that

in the germline, but not in somatic cells, redundancy in piRNA production among different

piRNA clusters is observed, with probably multiple piRNA clusters involved in the silencing

of the same TE. Moreover, many TE copies have acquired mutations and are non-functional for

transcription or for transposition. In the *flamΔZAM* line, although no *ZAM* piRNA was

produced, we did not detect any *ZAM* expression. However, when we introduced functional

copies of *ZAM*, *ZAM* was expressed demonstrating that depending on the genetic background,

the transposon landscape varies and functional copies can be absent or present. In general, the

TE content varies considerably among populations [47,51]. Interestingly, we identified *ZAM* copies

with a deletion that affects the *pol* gene. The copy numbers of this *ZAM* variant *ZAM-v2* and of

ZAM full-length elements (ZAM-fl) that have transposed in the RevI-H2 line are similar (4 and

6 copies respectively), suggesting that even this *ZAM*-variant can transpose very efficiently.

Studies in different organisms have shown that TEs rapidly diversify. For instance, the *mariner*

DNA transposon is present in 68 different versions in grass genomes [52]. Such rapid

diversification certainly promotes speciation of new families of active TEs.

One interesting question is how *ZAM* RNAs transit into the oocyte and at which stage during

Drosophila oogenesis *ZAM* transposes in germ cells. We noticed that *ZAM* RNAs, although

transcribed in follicle cells, were deposited and accumulated at the posterior pole of early

embryos, where future germ cells cellularize. *ZAM* might have evolved to preferentially

mobilize in the dividing primordial germ cells of the offspring instead of the developing oocyte,

which is not in a phase favorable to transposition because of its prolonged arrest in prophase I

associated with highly compacted chromatin[53].

Previous experiments demonstrated that *ZAM* RNAs accumulate in follicle cells when

vitellogenesis is defective, suggesting that *ZAM* transmission to the oocytes requires functional

vitellogenin trafficking [20] (Supplementary Video 1). Moreover, errantiviruses, such as *ZAM*

and *Gypsy*, can form pseudo-viral particles in follicle cells when they are expressed [17,19,20,24].

ZAM Gag and Env proteins are expressed in RevI-H2i2 follicle cells. Retroviral envelope

glycoproteins undergo proteolytic processing by cellular serine endoproteases (furin and

proprotein convertases), in order to produce the two functional subunits, a glycosylated

hydrophilic polypeptide (SU) and a transmembrane domain (TM). This step is necessary to

achieve protein competence to promote membrane fusion and virus infectivity [54,55]. The

errantiviral *env* gene, acquired from insect baculovirus [56], encodes a protein whose function is

analogous to that of retroviral Env protein, which is responsible for infectious properties.

Indeed, *ZAM* Env protein is composed of an SU, a TM and an Arg–X–Lys–Arg conserved

domain, which is considered to be a furin consensus proteolytic cleavage site [26,55,57]. A recent

study demonstrated that intracellular retrotransposition of the *Gypsy* errantivirus can occur in

the absence of the Env protein, while intercellular transmission requires a functional Env [19].

Currently, whether *ZAM* can transpose intracellularly, in follicle cells, and the exact

mechanisms (Env protein dependent or independent) used for *ZAM* transmission to the oocyte

are unknown.

Once a virus enters the target cells, several scenarios for retrovirus uncoating have been

proposed. Recent advances on the HIV-1 strongly suggest an uncoating at the nuclear pore and

within the nuclear compartment [58]. Errantiviruses also encode Gag proteins which are capable

of mediating the assembly of virus-like particles. However, there are significant differences

between these proteins and retroviral Gag proteins, which might lead to a different uncoating

process for errantiviruses [59]. In our study, we observed the loss of *ZAM* RNA in the oocyte

when germline *ZAM*-derived piRNAs are produced. We can hypothesize that the *ZAM* capsid

is dissociated soon after entry into the oocyte and that piRNAs can therefore easily target *ZAM*

RNAs. It is also possible that *ZAM* RNAs are still encapsidated in the oocyte, but the capsid

does not protect the *ZAM* RNA from piRNAs and their associated endonuclease. Previous

studies on virus-like particles of the yeast *Ty* retrotransposon suggest that these particles form

open structures that leave the RNA at the interior of the capsid accessible to RNase [60,61].

It has been proposed that in different species, an "innate" response at the piRNA or siRNA level

can be initiated in the gonads upon retrovirus invasion ([39,62–67]). We found that no clear innate

small RNA response is triggered upon *ZAM* reactivation in Drosophila ovaries. Total small-

RNA sequencing after *ZAM* reactivation revealed the presence of sense *ZAM*-mapping small

RNAs, but they lack characteristics of siRNAs or piRNAs. We hypothesize that these sense

small RNAs are degradation products generated when there is an excessive amount of *ZAM*

RNAs. Altogether, these results show that no initial small RNA response is mounted upon *ZAM*

reactivation, leaving follicle cells, where *ZAM* is expressed, and also oocytes unprotected

against *ZAM* transposition. Our findings suggest that the piRNA response is a robust response

that, in the case of *ZAM*, must be established either in the follicle cells or in the germ cells to

efficiently control the invading TE. However, the time required for developing a robust piRNA

response to sustainably control TE transposition remains unknown. Lastly, it is thought that the

piRNA pathway has no antiviral role in Drosophila [68]. However, it would be interesting to

determine whether this is also true if parts of the viral genome are integrated into a germline

piRNA cluster during infection.

Germline and somatic piRNA pathways and their respective piRNA clusters are distinct. There

is no ping-pong amplification of piRNAs in the somatic follicle cells and piRNA production in

these cells is almost exclusively dependent on a single piRNA cluster, *flamenco*, making it more

vulnerable to mutation. A key outcome of our results is that they suggest that not only does the

host adapt to the TE but the TE also seems to have adapted to the host: the exclusive expression

of *ZAM* in somatic cells allows the TE to "hide" in the follicle cells and invade an unprotected

germline after a simple deletion of a short *flam* sequence. The errantivirus *ZAM* thus seems to

have adapted to the host by gaining tissue specificity and by adopting an expression niche.

Methods

Fly stocks, transgenic lines, and crosses

Flies were maintained at 25°C under a light/dark cycle and 60% humidity. Between 3 and 6

days after hatching, flies were used for experiments. The RNAi lines against components of the

piRNA pathway used in this study are listed in **Supplementary Table S2**. Isogenic lines from

the RevI-H2 stock were generated by crossing a single female with a single male for five

generations. Germline and somatic knock-down have been performed using the nanos-gal4 and

the traffic-jam-gal4 driver lines respectively **(Supplementary Table S2)**. The Drosophila line

carrying the *ZAM* sensor is described in [28]. The sensor expresses the GFP reporter gene under

the control of an inducible Upstream Activation Sequence promoter (UASp) and harbors a *ZAM*

fragment in its 3′-UTR (pGFP-*ZAM*).

Single-molecule RNA fluorescence *in situ* hybridization (smRNA FISH) in ovaries and

embryos.

ZAM smRNA FISH was performed using 48 probes that target *ZAM* transcripts in a region that

is absent in the *ZAM* inserted in the *flamenco* piRNA cluster to detect only transcripts of active

ZAM copies (sequences in Supplementary Table S3). Ovaries from 3 to 6-day-old flies were

dissected in Schneider's Drosophila Medium and fixed in Fixing Buffer (4% formaldehyde,

0.3% Triton X-100, 1x PBS) for 20 min at room temperature, rinsed three times in 0.3% Triton

X-100, once in PBS, and permeabilized in 70% ethanol at 4°C overnight. Permeabilized ovaries

were rehydrated in smRNA FISH wash buffer (10% formamide in 2x SSC) for 10 min. Ovaries

were resuspended in 50µL hybridization buffer (10% dextran sulfate, 10% formamide in 2x

SSC) supplemented with 1µL of smRNA FISH probes. Hybridization was performed with

rotation at 37°C overnight. Ovaries were then washed twice with smRNA FISH wash buffer at

37°C for 30 min and twice with 2xSSC solution. Then, DNA was stained with DAPI (1/500

dilution in 2x SSC) at room temperature for 20 min. Ovaries were mounted in 30 µL

Vectashield mounting medium and imaged on a Zeiss LSM-980 or Zeiss LSM-800 confocal

microscope. The resulting images were processed using FIJI/ImageJ. The RNA signal

specificity was confirmed by adding 1 mg/mL of RNase A in 2x SSC for 2h before the

hybridization step.

For embryo staining, flies were caged and fed yeast paste. Embryos (0-2h) were collected,

dechorionated in 50% bleach for 4 min and rinsed in water. Eggs were fixed in 4%

paraformaldehyde/heptane for 20 min, devitellinized by vigorous shaking in 100% methanol

and stored in methanol at -20°C. Embryos were rehydrated with 1:1 methanol in 1xPBS, 0.1%

Tween-20 for 5 min and twice in 1xPBS, 0.1% Tween-20. Embryos were resuspended in

smRNA FISH wash buffer (10% formamide in 2x SSC) for 10 min and then processed for

smRNA FISH as described for ovaries. Immunostaining combined with smRNA FISH was

performed by adding primary antibodies to the smRNA FISH probes in the hybridization buffer

and incubating at 37°C overnight. Embryos were washed twice with smRNA FISH wash buffer

and incubated with the secondary antibody for 90 min. After two washes in 2x SSC, embryos

were mounted in 30 µL Vectashield mounting medium.

Immunofluorescence analysis of ovaries and embryos.

Ovaries from 3-6-day-old flies were dissected in supplemented Schneider's medium, ovarioles were separated, and the muscle sheath was removed before fixation to obtain undistorted follicles. Then, ovaries were fixed in 4% formaldehyde/1x PBS/2% Tween-20 for 15 min, rinsed three times with 1x PBS/2% Tween-20, and incubated 2 hours in PBT (1x PBS, 0.1% Triton X-100, 1% BSA). Ovaries were incubated with primary antibodies in PBT at 4°C overnight (antibodies are described in Supplementary Table S4). After three washes in PBT, ovaries were incubated with the corresponding secondary antibodies coupled to Alexa-488 or Cy3 for 90 min. After two washes in 1x PBS, DNA was stained with DAPI (1/500 dilution in 1x PBS) for 20 min. Ovaries were mounted in 30 μL Vectashield mounting medium and imaged on a Zeiss LSM-980 or Zeiss LSM-800 confocal microscope. The resulting images were processed using FIJI/ImageJ.

RT-qPCR analysis of transposon expression

10-20 pairs of dissected ovaries were homogenized in TRIzol reagent (Ambion). Following DNase I treatment, cDNA was prepared from 1 μg RNA by random priming of total RNA using Superscript IV Reverse Transcriptase (ThermoFisher Scientific). Quantitative PCR was performed with Roche FastStart SYBR Green Master on a the Lightcycler® 480 Instrument. RT-qPCR was used for quantification of transposon mRNA levels (primer sequences in Supplementary Table S5). All experiments were done with three biological replicates and with technical triplicates. Steady-state RNA levels were calculated from the threshold cycle for amplification with the $2^{-\Delta\Delta CT}$ method; *rp49* was used for normalization.

Immunoprecipitation of Piwi-ribonucleoprotein complexes

For each genotype, 50 pairs of ovaries from 3-6-day-old flies were dissected, lysed in 1 ml lysis

buffer (20 mM HEPES-NaOH at pH 7.0, 150 mM NaCl, 2.5 mM $MgCl_2$, 250 mM sucrose,

0.05% NP40, 0.5% Triton X-100, 1x Roche-Complete). Samples were cleared by centrifugation

at $10000 \times g$ at 4°C for 10 min. Extracts were incubated with rotation with rabbit polyclonal

anti-Piwi antibodies (4 µg per sample) at 4°C for 4h followed by overnight incubation with

Dynabeads[TM] Protein A (50 µl, Invitrogen, 10002D) at 4°C with rotation. Before incubation,

beads were equilibrated in NT2 buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM $MgCl_2$,

0.05% NP40). Beads were washed twice with ice-cold NT2 and twice with NT2 in which NaCl

concentration was adjusted to 300 mM. Nucleic acids that co-immunoprecipitated with Piwi

were isolated by treating beads with 0.7 mg/ml proteinase K in 0.3ml proteinase K buffer (0.5%

SDS, 10mM Tris-HCl pH 7.4, 50mM NaCl, 5mM EDTA), followed by phenol/chloroform

extraction (phenol at neutral pH) and ethanol precipitation.

DNA Isolation, Oxford Nanopore Technology sequencing and genome analysis

DNA was extracted from 200 RevI-H2i2 females using the Qiagen Blood & Cell Culture DNA

Midi kit. The genomic DNA quality and quantity were evaluated using a Femto Pulse (Agilent)

and a Qbit 3.0 (Invitrogen) respectively. Oxford Nanopore Technology (ONT) sequencing was

performed by I2BC (Gif-sur-Yvette, France) using five micrograms of genomic DNA. Adapter-

trimmed ONT reads were analyzed using NCBI Blastn

(https://blast.ncbi.nlm.nih.gov/Blast.cgi) or command-line Blastn (Blastn 2.8.1). The RevI-

H2i2 ONT reads containing *ZAM* insertions were detected by Blastn with the reference *ZAM*

[22], Repbase *ZAM*_I and *ZAM*_LTR sequences (https://www.girinst.org/repbase/, [29]). The *ZAM*

containing reads were then recovered with bedtools getfasta

(https://bedtools.readthedocs.io/en/latest/content/tools/getfasta.html, [69]). The *ZAM* insertion

sites where determined using Blastn of the *ZAM* containing reads to the *D. melanogaster*

Release 6 genome (http://flybase.org). The absence of empty sites, without a given *ZAM*

insertion, was verified by Blastn of the respective empty insertion sites, recovered from the *D.*

melanogaster Release 6 genome, to all ONT reads. Sequencing data are available in NCBI GEO

database (GSE213456).

RNA-sequencing and analysis

3 independent total RNA extractions from 30 ovaries from 3-6-day-old RevI-H2i2 flies using

Trizol (Invitrogen) were performed. Strand-specific libraries for RNA sequencing (RNA-Seq)

were constructed at BGI. 1 µg of total RNA was used to prepare mRNA library using MGIEasy

RNA Library Prep kit and sequenced as PE150 reads on the DNBSEQ G400 sequencer, and

adapter-clipped reads were provided by BGI. The data were analyzed on the local Galaxy

platform using HISAT2 alignment (Galaxy Version 2.1.0). The reads were first mapped to

ZAM-fl and to *ZAM-v2* using the "Disable spliced alignment" option. The mapped reads were

then aligned to ZAM_I sequence (Repbase) with the default options, i.e. allowing split

alignment. Reads were visualized using "Integrative Genomics Viewer" version 2.16.1. The

coverage of RNA-seq reads corresponding to *ZAM-v2* was determined as the number of split

reads specific to the *ZAM-v2* deletion at positions ZAM_I:5494-6120, normalized to the

average coverage of the pointed transcript. Coverage of RNA-seq reads corresponding to ZAM-

fl and ZAM-v2 was determined as the number of non-split reads at position 5495, the left edge

of the deletion, normalized to the average coverage of the pointed transcript. Only the left edge

was used for this purpose, as the right edge of the deletion is also mapped by reads

corresponding to ZAM-variants with other internal deletions (green in Figure 1a).

Small RNA sequencing

Regulatory small RNA extraction was performed as described in [70]. Briefly, 50 pairs of ovaries

from 3-6-day-old flies were lysed and Argonaute-small RNA complexes were isolated using

TraPR ion exchange spin columns (Lexogen, Catalog Nr.128.08). Total RNA also was

extracted for some samples (80-100 ovaries for each sample) using the classical TRIzol

extraction, followed by 2S rRNA depletion and size selection before sequencing. Sequencing

was performed by Fasteris SA (Geneva, Switzerland) on an Illumina NextSeq550 instrument

(13-15 million reads per sample).

Illumina small RNA sequencing reads were loaded on the small RNA analysis pipeline

sRNAPipe [71] for mapping to the various genomic sequence categories of the *D. melanogaster*

genome (Release 6). For the analysis, 23-29nt genome mappers were selected as piRNAs, and

21nt genome mappers were selected as siRNAs. "Genome-unique" piRNAs were defined as

23-29 reads that mapped uniquely across the reference genome. piRNAs were mapped to TEs

allowing up to 3 mismatches, siRNAs allowing up to 1 mismatch, and genome-unique piRNAs

to piRNA clusters as defined in [11] allowing no mismatch. The window size was of 91nt for the

entire *ZAM*, 86 nt for ZAM_I and 140nt for the *flamenco* region at X:21,769,891..21,789,891

to establish the piRNA density profiles. For comparison between samples, all read counts were

normalized by the number of piRNA/siRNA reads used as input (genome-mapped piRNAs or

siRNAs, genome-unique piRNAs) and represented in RPM [RPM = read-count * 1,000,000 /

(total of genome mapping piRNAs)], or RPKM [RPM = read-count * 1,000,000 / (TE

Length/1000) / (total of genome mapping piRNAs)] in the case of density profiles. To assess

the ping-pong signature, the counts of 1 to 23nt 5'-overlaps were determined, and the percentage

of 10nt 5'-overlaps over the total 1-23nt 5'-overlaps was calculated. The Z-score for 10nt

5'overlaps was determined using the percentages of all 1 to 23nt-long 5'overlaps as a

background and was considered significant when it was >1.96. Scatter plots were done with

RStudio with antisense piRNAs or siRNAs mapping to the respective internal sequence of TEs

(allowing 0-3 mismatches for piRNAs and 0-1 mismatch for siRNAs). All small RNA

sequencing done for this study is listed in Supplementary Table S6. Small-RNA sequencing

data are available in NCBI GEO database (GSE213368).

Sterility tests

For the sterility tests, RevI-H2i2 homozygous females were compared to w^{1118} females, and

homozygous *flamΔZAM* females that carry three functional *ZAM* copies from the RevI-H2 X

chromosome were compared to *flamΔZAM* females without these functional *ZAM* copies in

their genome. Sterility tests were performed at 25° C. Thirty 3-6-day-old virgin females of each

genotype were individually mated with three w^{1118} males, and eggs were collected for 24 hours.

The number of eggs laid by each female was determined. Then, eggs were kept at 25°C for

another 24 hours before determining the egg hatching rate. The experiment was done twice for

a total of approximatively 60 replicates for each condition.

Generation of the *flamΔZAM* line using the CRISPR-Cas9 technology

The *ZAM* copy in the *flamenco* piRNA cluster was deleted using a pCFD6 plasmid that

expresses two single guide RNAs (sgRNAs) under the Gal4/UAS system. The sgRNAs were

designed to target genome-unique sequences located upstream and downstream of the *flamenco*

ZAM copy: TTGTAGCGCTCTTCTTCTCT (sgRNA *flamΔZAM_1*) and

AGCGCAACCACGTACAGCGA (sgRNA *flamΔZAM_2*). The pCFD6 plasmid harboring

these sgRNAs was injected by the Bestgene company into embryos from the BL#9736 stock

(Bloomington stock center) for integration of the plasmid into the genomic site 53B2. The

obtained flies were crossed with nanos-gal4; UAS-Cas9 flies (BL#54593, Bloomington stock

center). Prior to crossing, the X chromosome of each of these lines was replaced by the X

chromosome of the Iso1A *Drosophila* line. After the crosses, 500 lines were derived and

screened by PCR using primers specific for the *flamenco ZAM* copy. The detailed crossing

schemes are available upon request. Lines without amplification of internal *flamenco ZAM*

sequences were selected for PCR amplification of the target locus with primers that framed the

flamenco ZAM copy and the target sequences of the sgRNAs. The obtained amplicons were

sequenced.

ACKNOWLEDGEMENTS

We thank the *Bloomington Stock Center* for providing stocks. We thank J. Brennecke for

providing antibodies. We thank www.flybase.org, "http://www.girinst.org"and NCBI for

providing databases and tools. We thank S. Chambeyron and K. Senti for helpful discussions,

A. Molaro and the members of the Brasset laboratory for comments on the manuscript. We

thank C. Vaury for having established the original RevI-H2 line over 30 years ago, and for

preserving it all these years. We thank Y. Renaud and P. Pouchin for helpful advices and

development of the iGReD bioinfomatics platform. We also thank the CLIC facility (Clermont

Imagerie Confocale). We thank Gentyane Facility for the Quality Control of gDNA.

AUTHOR CONTRIBUTIONS

Conceptualization, MY, SJ and EB; Validation and Investigation, MY, SMM, AA, NG, BB,

Data curation and bioinformatic analyses, MY, SJ, writing—original draft, MY and EB;

writing—review and editing, MY, SJ and EB; Supervision, SJ and EB, funding acquisition,

MY and EB.

FUNDING

This work was supported by grants from the Agence Nationale pour la Recherche (CHApiTRE

ANR-20-CE12-0005, BiopiC ANR-21-CE12-0022, and EpiTET ANR-17-CE12-0030-03), the

La Fondation ARC pour la recherche sur le cancer (PJA20171206129). M.Y. was supported by

the Ministère de l'Enseignement Supérieur et de la Recherche and the Fondation pour la

Recherche Médicale (FDT202106012950). This research was financed by the French

government IDEX-ISITE initiative 16-IDEX-0001 (CAP 20-25). The funders had no role in

study design, data collection and analysis, decision to publish, or preparation of the manuscript.

COMPETING INTERESTS

The authors declare that no competing interest exists.

708
709
710 REFERENCES
711
712
1.   Dewannieux, M. *et al.* The mouse IAPE endogenous retrovirus can infect cells through

any of the five GPI-anchored Ephrin A proteins. *PLoS Pathog.* **7**, e1002309 (2011).

2.   Frank, J. A. *et al.* Evolution and antiviral activity of a human protein of retroviral origin.

Science **378**, 422–428 (2022).

3.   Grow, E. J. *et al.* Intrinsic retroviral reactivation in human preimplantation embryos and

pluripotent cells. *Nature* **522**, 221–225 (2015).

4.   Svoboda, P. *et al.* RNAi and expression of retrotransposons MuERV-L and IAP in

preimplantation mouse embryos. *Dev. Biol.* **269**, 276–285 (2004).

5.   Tokuyama, M. *et al.* ERVmap analysis reveals genome-wide transcription of human

endogenous retroviruses. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 12565–12572 (2018).

6.   Gerdes, P., Richardson, S. R., Mager, D. L. & Faulkner, G. J. Transposable elements in the

mammalian embryo: pioneers surviving through stealth and service. *Genome Biol.* **17**,

100 (2016).

7.   Nicolau, M., Picault, N. & Moissiard, G. The Evolutionary Volte-Face of Transposable

Elements: From Harmful Jumping Genes to Major Drivers of Genetic Innovation. *Cells*

10, (2021).

8.   Ozata, D. M., Gainetdinov, I., Zoch, A., O'Carroll, D. & Zamore, P. D. PIWI-interacting

RNAs: small RNAs with big functions. *Nat. Rev. Genet.* **20**, 89–108 (2019).

9.   Czech, B. *et al.* piRNA-Guided Genome Defense: From Biogenesis to Silencing. *Annu.*

Rev. Genet. **52**, 131–157 (2018).

10. King, R. C., Aggarwal, S. K. & Aggarwal, U. The development of the female Drosophila

reproductive system. *J. Morphol.* **124**, 143–166 (1968).

11. Brennecke, J. *et al.* Discrete small RNA-generating loci as master regulators of

transposon activity in Drosophila. *Cell* **128**, 1089–1103 (2007).

12. Pélisson, A. *et al.* Gypsy transposition correlates with the production of a retroviral

envelope-like protein under the tissue-specific control of the Drosophila flamenco gene.

EMBO J. **13**, 4401–4411 (1994).

13. Desset, S., Meignin, C., Dastugue, B. & Vaury, C. COM, a heterochromatic locus

governing the control of independent endogenous retroviruses from Drosophila

melanogaster. *Genetics* **164**, 501–509 (2003).

14. Zanni, V. *et al.* Distribution, evolution, and diversity of retrotransposons at the

flamenco locus reflect the regulatory properties of piRNA clusters. *Proc. Natl. Acad. Sci.*

U. S. A. **110**, 19842–19847 (2013).

15. Desset, S., Buchon, N., Meignin, C., Coiffet, M. & Vaury, C. In Drosophila melanogaster

the COM locus directs the somatic silencing of two retrotransposons through both Piwi-

dependent and -independent pathways. *PLoS One* **3**, (2008).

16. Lau, N. C. *et al.* Abundant primary piRNAs, endo-siRNAs, and microRNAs in a Drosophila

ovary cell line. *Genome Res.* **19**, 1776–1785 (2009).

17. Leblanc, P. *et al.* Life Cycle of an Endogenous Retrovirus, ZAM, in Drosophila

melanogaster. *J. Virol.* **74**, 10658–10669 (2000).

18. Song, S. U., Kurkulos, M., Boeke, J. D. & Corces, V. G. Infection of the germ line by

retroviral particles produced in the follicle cells: A possible mechanism for the

mobilization of the gypsy retroelement of Drosophila. *Development* **124**, 2789–2798

(1997).

19. Keegan, R. M., Talbot, L. R., Chang, Y. H., Metzger, M. J. & Dubnau, J. Intercellular viral

spread and intracellular transposition of Drosophila gypsy. *PLoS Genet.* **17**, 1–22 (2021).

20. Brasset, E. *et al.* Viral particles of the endogenous retrovirus ZAM from Drosophila

melanogaster use a pre-existing endosome/exosome pathway for transfer to the

oocyte. *Retrovirology* **3**, 1–9 (2006).

21. Tcheressiz, S. *et al.* Expression of the Idefix retrotransposon in early follicle cells in the

germarium of Drosophila melanogaster is determined by its LTR sequences and a

specific genomic context. *Mol. Genet. Genomics* **267**, 133–141 (2002).

22. Sokolova, O. A. *et al.* Special vulnerability of somatic niche cells to transposable

element activation in Drosophila larval ovaries. *Sci. Rep.* **10**, (2020).

23. Malone, C. D. *et al.* Specialized piRNA Pathways Act in Germline and Somatic Tissues of

the Drosophila Ovary. *Cell* **137**, 522–535 (2009).

24. Chalvet, F. *et al.* Proviral amplification of the Gypsy endogenous retrovirus of

Drosophila melanogaster involves env-independent invasion of the female germline.

EMBO J. **18**, 2659–2669 (1999).

25. Bline, A. P., Le Goff, A. & Allard, P. What Is Lost in the Weismann Barrier? *Journal of*

developmental biology **8**, (2020).

26. Leblanc, P., Desset, S., Dastugue, B. & Vaury, C. Invertebrate retroviruses: ZAM a new

candidate in D. melanogaster. *EMBO J.* **16**, 7521–7531 (1997).

27. Desset, S. *et al.* Mobilization of two retroelements, ZAM and Idefix, in a novel unstable

line of Drosophila melanogaster. *Mol. Biol. Evol.* **16**, 54–66 (1999).

28. Duc, C. *et al.* Trapping a somatic endogenous retrovirus into a germline piRNA cluster

immunizes the germline against further invasion. *Genome Biol.* **20**, 1–14 (2019).

29. Jurka, J. *et al.* Repbase Update, a database of eukaryotic repetitive elements.

Cytogenet. Genome Res. **110**, 462–467 (2005).

30. George, P. *et al.* Increased production of piRNAs from euchromatic clusters and genes

in Anopheles gambiae compared with Drosophila melanogaster. *Epigenetics and*

Chromatin **8**, (2015).

31. Czech, B. & Hannon, G. J. One Loop to Rule Them All: The Ping-Pong Cycle and piRNA-

Guided Silencing. *Trends Biochem. Sci.* **41**, 324–337 (2016).

32. Meignin, C., Dastugue, B. & Vaury, C. Intercellular communication between germ line

and somatic line is utilized to control the transcription of ZAM, an endogenous

retrovirus from Drosophila melanogaster. *Nucleic Acids Res.* **32**, 3799–3806 (2004).

33. Atallah, J. & Lott, S. E. Evolution of maternal and zygotic mRNA complements in the

early Drosophila embryo. *PLoS Genet.* **14**, e1007838 (2018).

34. Aravin, A. A. & Hannon, G. J. Small RNA silencing pathways in germ and stem cells. *Cold*

Spring Harb. Symp. Quant. Biol. **73**, 283–290 (2008).

35. Khurana, J. S. & Theurkauf, W. piRNAs, transposon silencing, and Drosophila germline

development. *J. Cell Biol.* **191**, 905–913 (2010).

36.   Saito, K. & Siomi, M. C. Small RNA-mediated quiescence of transposable elements in

797   animals. *Dev. Cell* **19**, 687–697 (2010).

798   37.   Klattenhoff, C. *et al.* Drosophila rasiRNA pathway mutations disrupt embryonic axis

799   specification through activation of an ATR/Chk2 DNA damage response. *Dev. Cell* **12**,

800   45–55 (2007).

801   38.   Parameswaran, P. *et al.* Six RNA viruses and forty-one hosts: viral small RNAs and

802   modulation of small RNA repertoires in vertebrate and invertebrate systems. *PLoS*

803   *Pathog.* **6**, e1000764 (2010).

804   39.   Yu, T. *et al.* The piRNA Response to Retroviral Invasion of the Koala Genome. *Cell* **179**,

805   632-643.e12 (2019).

806   40.   Le Rouzic, A. & Capy, P. The first steps of transposable elements invasion: Parasitic

807   strategy vs. genetic drift. *Genetics* **169**, 1033–1043 (2005).

808   41.   Kofler, R., Senti, K. A., Nolte, V., Tobler, R. & Schlötterer, C. Molecular dissection of a

809   natural transposable element invasion. *Genome Res.* **28**, 824–835 (2018).

810   42.   Robillard, É., Le Rouzic, A., Zhang, Z., Capy, P. & Hua-Van, A. Experimental evolution

811   reveals hyperparasitic interactions among transposable elements. *Proc. Natl. Acad. Sci.*

812   *U. S. A.* **113**, 14763–14768 (2016).

813   43.   Schaack, S., Gilbert, C. & Feschotte, C. Promiscuous DNA: Horizontal transfer of

814   transposable elements and why it matters for eukaryotic evolution. *Trends Ecol. Evol.*

815   **25**, 537–546 (2010).

816   44.   Wierzbicki, F., Kofler, R. & Signor, S. Evolutionary dynamics of piRNA clusters in

817   Drosophila. *Mol. Ecol.* 1–17 (2021).

818   45.   Yoth, M., Jensen, S. & Brasset, E. The Intricate Evolutionary Balance between

819   Transposable Elements and Their Host: Who Will Kick at Goal and Convert the Next Try?

820   *Biology* **11**, (2022).

821   46.   Mohn, F., Sienski, G., Handler, D. & Brennecke, J. The Rhino-Deadlock-Cutoff complex

822   licenses noncanonical transcription of dual-strand piRNA clusters in Drosophila. *Cell*

823   **157**, 1364–1379 (2014).

824   47.   Luo, S. *et al.* The evolutionary arms race between transposable elements and piRNAs in

825   Drosophila melanogaster. *BMC Evol. Biol.* **20**, 1–18 (2020).

826   48.   Gebert, D. *et al.* Large Drosophila germline piRNA clusters are evolutionarily labile and

827   dispensable for transposon regulation. *Mol. Cell* 1–14 (2021).

828   49.   Shpiz, S., Ryazansky, S., Olovnikov, I., Abramov, Y. & Kalmykova, A. Euchromatic

829   Transposon Insertions Trigger Production of Novel Pi- and Endo-siRNAs at the Target

830   Sites in the Drosophila Germline. *PLoS Genet.* **10**, (2014).

831   50.   Kofler, R. Dynamics of transposable element invasions with piRNA clusters. *Mol. Biol.*

832   *Evol.* **36**, 1457–1472 (2019).

833   51.   Lerat, E. *et al.* Population-specific dynamics and selection patterns of transposable

834   element insertions in European natural populations. *Mol. Ecol.* **28**, 1506–1522 (2019).

835   52.   Feschotte, C. & Wessler, S. R. Mariner-like transposases are widespread and diverse in

836   flowering plants. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 280–285 (2002).

837   53.   Navarro-Costa, P. *et al.* Early programming of the oocyte epigenome temporally

838   controls late prophase i transcription and chromatin remodelling. *Nat. Commun.* **7**,

839   (2016).

840   54.   Bergeron, F., Leduc, R. & Day, R. Subtilase-like pro-protein convertases: from molecular

841   specificity to therapeutic applications. *J. Mol. Endocrinol.* **24**, 1–22 (2000).

55. Klenk, H. D. & Garten, W. Host cell proteases controlling virus pathogenicity. *Trends*

Microbiol. **2**, 39–43 (1994).

56. Malik, H. S., Henikoff, S. & Eickbush, T. H. Poised for contagion: evolutionary origins of

the infectious abilities of invertebrate retroviruses. *Genome Res.* **10**, 1307–1318 (2000).

57. Hosaka, M. *et al.* Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by

furin within the constitutive secretory pathway. *J. Biol. Chem.* **266**, 12127–12130

(1991).

58. Guedán, A., Caroe, E. R., Barr, G. C. R. & Bishop, K. N. The Role of Capsid in HIV-1

Nuclear Entry. *Viruses* **13**, (2021).

59. Syomin, B. V., Kandror, K. V., Semakin, A. B., Tsuprun, V. L. & Stepanov, A. S. Presence of

the gypsy (MDG4) retrotransposon in extracellular virus-like particles. *FEBS Lett.* **323**,

285–288 (1993).

60. Palmer, K. J. *et al.* Cryo-electron microscopy structure of yeast Ty retrotransposon virus-

like particles. *J. Virol.* **71**, 6863–6868 (1997).

61. Burns, N. R. *et al.* Symmetry, flexibility and permeability in the structure of yeast

retrotransposon virus-like particles. *EMBO J.* **11**, 1155–1164 (1992).

62. Kolliopoulou, A. *et al.* PIWI pathway against viruses in insects. *Wiley Interdiscip. Rev.*

RNA **10**, e1555 (2019).

63. Rozhkov, N. V. *et al.* Small RNA-based silencing strategies for transposons in the process

of invading Drosophila species. *RNA* **16**, 1634–1645 (2010).

64. Rozhkov, N. V. *et al.* Evolution and dynamics of small RNA response to a retroelement

invasion in drosophila. *Mol. Biol. Evol.* **30**, 397–408 (2013).

65. Kawamura, Y. *et al.* Drosophila endogenous small RNAs bind to Argonaute 2 in somatic

cells. *Nature* **453**, 793–797 (2008).

66. Rehwinkel, J. *et al.* Genome-Wide Analysis of mRNAs Regulated by Drosha and

Argonaute Proteins in Drosophila melanogaster. *Mol. Cell. Biol.* **26**, 2965–2975 (2006).

67. Katsuma, S. *et al.* Transcriptome profiling reveals infection strategy of an insect

maculavirus. *DNA Res.* **25**, 277–286 (2018).

68. Petit, M. *et al.* piRNA pathway is not required for antiviral defense in Drosophila

melanogaster. *Proceedings of the National Academy of Sciences* **113**, E4218–E4227

(2016).

69. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic

features. *Bioinformatics* **26**, 841–842 (2010).

70. Grentzinger, T. *et al.* A universal method for the rapid isolation of all known classes of

functional silencing small RNAs. *Nucleic Acids Res.* **48**, (2020).

71. Pogorelcnik, R., Vaury, C., Pouchin, P., Jensen, S. & Brasset, E. sRNAPipe: A Galaxy-based

pipeline for bioinformatic in-depth exploration of small RNAseq data. *Mob. DNA* **9**, 4–9

(2018).

Figure 1: *ZAM* is expressed in follicle cells in the RevI-H2i2 isogenic line but the line is stable.

a. *ZAM* elements in the RevI-H2i2 genome. Each triangle represents a *ZAM* insertion. The different ZAM-variants are presented in the illustration on the right. The positions refer to *ZAM* internal sequences (*ZAM*_I in RepBase). Blue: full-length *ZAM* elements (ZAM-fl); violet: *ZAM* variants *ZAM-v1* with deleted 5'-UTR; orange: *ZAM*-variants *ZAM-v2*, in which positions 5494-6120 are deleted; yellow: ZAM-variants ZAM-v3 with a 303 bp deletion in the 5'-UTR; green: *ZAM* with internal deletions other than *ZAM* variants above; gray: full-length *ZAM* copy also present in the reference Release 6 genome (http://flybase.org). The dotted box indicates four *ZAM* copies on the X chromosome inserted in referenced germline piRNA clusters (Cluster

9 and 13). No *ZAM* insertion was found in chromosome 4 (1.35 Mb, not shown). For coordinates
and details see Supplementary Table 1. **b**. Projection of confocal images of ovarioles,
germarium, and stage 10 follicles showing *ZAM* expression by smRNA FISH (in red) in RevI-
H2i2 ovaries. DNA was stained with DAPI (white). **c**. Fold-change in the steady-state *ZAM*,
Gypsy and *Burdock* RNA levels for RevI-H2i2 ovaries compared with w^{1118} ovaries (control),
quantified by RT-qPCR (primer sequences in Supplementary Table 5). At least three biological
replicates and three technical replicates were used. *******p-value* <0.01; ns, not-significant (*p-value*
>0.05) (Mann-Whitney test). Error bars indicate the standard deviation (SD). **d**. Confocal
sections of stage 10 egg chambers of RevI-H2i2 and w^{1118} control line showing *ZAM*-encoded
Gag (green) and Env (red) proteins. DNA was stained with DAPI (white). **e**. Morphology of
control and RevI-H2i2 ovaries. **f.** Box plot displaying the number of eggs laid per fly per day
by control and RevI-H2i2 females. Each dot represents an individual female. The midline
indicates the median value, and the box shows the first and third quartile. Error bars indicate
the SD. ns, not-significant (*p-value* >0.05) (Mann-Whitney test).
915
916

Figure 2: Germline *ZAM* piRNAs produced in RevI-H2i2 germ cells counteract *ZAM* invasion.

a. Density plot of *ZAM*-mapping regulatory piRNAs along the *ZAM* sequence in RevI-H2i2 ovaries (up to 3 mismatches). In the lower right corner is the histogram showing the percentage of 5'-overlaps between sense and antisense *ZAM*-derived piRNAs (23–29 nt) in RevI-H2i2 ovaries. The proportion of 10nt 5'-overlaps is in red and the corresponding Z-score is indicated. **b.** Antisense piRNAs mapping to TE internal sequences (0-3 mismatches) in the RevI-H2i2 line upon *white-* (control), *ago3-,* or *piwi*-GLKD. Normalized per million of genome-mapping piRNAs. **c.** Histogram showing the percentage of 5'-overlaps between sense and antisense *ZAM*-mapping piRNAs (up to 3 mismatches) in *white-, ago3-,* or *piwi*-GLKD RevI-H2i2 ovaries. The percentage of 10nt overlaps is in red and the corresponding Z-score is indicated. **d.** Color-inverted confocal images of stage 10 egg chambers showing *ZAM* smRNA FISH signal in ovaries of the indicated genotypes. **e.** Bar plot showing the percentage of stage 10 follicles with *ZAM* RNA detected in the ooplasm by smRNA FISH of RevI-H2i2 ovaries with the indicated GLKD. This experiment was done three times and approximately 50 follicles per conditions were observed for each experiment. Error bars indicate the SD. **f.** Scatter plot showing the normalized counts of antisense Piwi-bound piRNAs mapping to individual internal TEs sequences in control ovaries (*white*-sKD) and *vret*-sKD ovaries. Antisense piRNA counts, mapped allowing up to 3 mismatches, were normalized per million of genome-mapping piRNAs (RPM, here in logarithmic scale). TEs in red have a *vret*-sKD/*white*-sKD ratio <0.3. *ZAM* is boxed black. **g.** Confocal images of ovarioles showing *ZAM* smRNA FISH signal (in red) in *white-* (control) and v*ret*-sKD ovaries. DNA was stained with DAPI (white). **h.** Color-inverted confocal projection of stage 10 egg chamber showing *ZAM smRNA* FISH signal in *vret*-sKD ovaries. **i.** Bar plot showing the percentage of stage 10 follicles with *ZAM* RNA invasion of the ooplasm, assessed by *ZAM* smRNA FISH, of *white-* (control) and *vret*-sKD ovaries. This experiment was done twice and ~50 follicles per condition were observed for each experiment. Error bars indicate the SD.

949
950
Figure 3: *ZAM* RNAs transcribed in the follicle cells transit to the oocyte and are deposited in early embryos.

a. Confocal images of stage 10 follicles in the RevI-H2i2 *piwi*-GLKD line. *Burdock* (green) and *ZAM* (red) mRNAs were detected by smRNA FISH. DNA was stained with DAPI (blue). **b**. Fold-change in the steady-state *ZAM*, *Burdock* and *Piwi* RNA levels for RevI-H2i2 *piwi*-GLKD ovaries compared with RevI-H2i2 *white*-GLKD ovaries (control), quantified by RT-qPCR (primer sequences in Supplementary Table 5). At least three biological replicates and three technical replicates were used. *: *p*-value < 0.05, **: p-*value* <0.01; ns, not significant (*p-value* >0.05) (Mann-Whitney test). Error bars indicate the standard deviation (SD) **c.** Confocal

images of ovarioles and of an isolate stage 8 egg chamber in the RevI-H2i2 *ago3*-GLKD line.
Burdock (green) and *ZAM* (red) mRNAs were detected by smRNA FISH. DNA was stained
with DAPI (blue). **d.** Color-inverted confocal images showing *ZAM* smRNA FISH signal in
early embryos collected 0-2 hours after egg laying (AEL). Mothers were from the indicated
genotype. **e.** Zoom on the posterior part of a *vret*-sKD early embryo collected at 0-1 hours AEL
showing *ZAM* RNA accumulation at the posterior pole. **f.** Color-inverted confocal images
showing *ZAM* smRNA FISH signal in embryos laid by *vret*-sKD females at the indicated
developmental stages.
968

969
970

Figure 4: *ZAM* deletion from the *flamenco* piRNA cluster leads to *ZAM* reactivation and
oocyte invasion.
a. Density plots showing genome-unique piRNAs mapping over 20 kb of the *flamenco* piRNA
cluster (without mismatch) where the *ZAM* insertion is located (Release 6:
X:21,769,891..21,789,891) in the control (Iso1A) and *flamΔZAM* lines. The position of the
flamenco ZAM copy *(ZAM-flam)* is indicated. The positions of the sgRNAs used for *ZAM-flam*
deletion by CRISPR-Cas9 are shown in red. **b.** Density plot of *ZAM*-mapping regulatory
piRNAs along the *ZAM* sequence in control and *flamΔZAM* ovaries (up to 3 mismatches). **c.**
Scatter plot showing the normalized counts of antisense regulatory piRNAs mapping to
individual internal TE sequences in control ovaries (Iso1A) versus *flamΔZAM* ovaries.
Antisense piRNA counts, mapped allowing up to 3 mismatches, were normalized per million
of genome-mapping piRNAs (RPM, here in logarithmic scale). TEs in red have a
flamΔZAM/Iso1A ratio <0.3. **d.** Color-inverted confocal images of ovarioles (upper panels) and
stage 10 egg chambers (lower panels) from the indicated genotypes showing *ZAM* smRNA
FISH signal. **e.** Ovaries of the *flamΔZAM* line and of the *flamΔZAM* line with three recent *ZAM*
copies introduced by genetic crossing and X chromosome recombination with the RevI-H2 line.
f. Box plot displaying the number of eggs laid per fly per day by RevI-H2i2, *flamΔZAM and*
flamΔZAM females with three recent *ZAM* copies. Each dot represents an individual female.
The midline indicates the median value, and the box shows the first and third quartile. Error
bars indicate the SD. ***p-value* <0.001; ns, not-significant (*p-value* >0.05) (Mann-Whitney
test).

992
993
Figure 5: No initial piRNA and siRNA response after *ZAM* retrotransposon reactivation
a. Density plot of regulatory piRNAs along the *ZAM* internal sequence in ovaries from a control
line (*white*-sKD) and from the *flamΔZAM*-RevI-H2i2 chr III line (up to 3 mismatches). **b.**
Scatter plots showing the normalized counts of regulatory piRNAs mapping to individual
internal TE sequences in control ovaries (*white-sKD*) versus *flamΔZAM*-RevI-H2i2 chr III
ovaries. piRNA counts, mapped allowing up to 3 mismatches, were normalized per million of
genome-mapping piRNAs (RPM, here in logarithmic scale). **c**. Density plot of *ZAM*-mapping
regulatory siRNAs (21nt small-RNAs complexed with Argonaute proteins) along the *ZAM*
internal sequence produced in control (*white*-sKD) and in *flamΔZAM* RevI-H2i2 chr III ovaries
(0-1 mismatch). **d**. Scatter plot showing the normalized counts of antisense regulatory siRNAs
mapping to individual internal TE sequences in control ovaries (*white-sKD*) versus *flamΔZAM*
RevI-H2i2 chr III ovaries. Antisense siRNA counts, mapped allowing up to 1 mismatch, were
normalized per million of genome-mapping siRNAs (RPM, here in logarithmic scale).
1007
1008

1009

1010

Supplementary Figure 1 (related to Figure 1)
a. Color-inverted confocal images of ovarioles from RevI-H2i2 ovaries showing *ZAM* RNA
signal without (left panel) and after (right panel) RNase A treatment. **b.** Color-inverted confocal
images of ovarioles showing that *ZAM* RNA is completely absent in Iso1A, w^{1118}, and w^{IR6}
ovaries. **c.** Mapping of mRNA-Seq reads of the full-length *ZAM* (*ZAM-fl*) and of *ZAM-v2* to the
reference *ZAM* internal sequences *ZAM_I* (Repbase) allowing splitting of the reads. Above is
shown *ZAM-v2* structure. The inset below shows a zoom on the *ZAM-v2* deletion with the
corresponding split reads. Reads corresponding to *ZAM* mRNA are in blue, antisense reads are
in red. Positions of the shown regions within *ZAM_I* are indicated. d. Coverage of mRNA-seq
reads corresponding to the indicated *ZAM*-variants normalized to the average coverage of the
gene *pointed*.
1022

1026 **Supplementary Figure 2 (related to Figure 2)**

a. Confocal images of ovarioles with GFP (green) and DNA (white) staining. Ovarioles of the progeny of a cross between either w^{1118} control females or RevI-H2i2 females and males carrying the pGFP-*ZAM* sensor transgene driven by actin-Gal4. **b.** Antisense regulatory piRNAs (23-29 small-RNAs complexed with Argonaute proteins) mapping to TE internal sequences (0-3 mismatches) in the RevI-H2i2 line upon *white*- (control), or *zuc*-GLKD. Normalized per million of genome-mapping piRNAs. **c.** Box plot displaying the Z-score distribution of 10nt 5'-overlaps for TE-mapping piRNAs in the *white*-GLKD and *ago3*-GLKD RevI-H2i2 lines. Each dot represents a TE with a Z-score >1.96 (dotted line) in the control condition (*white*-GLKD). *ZAM* is highlighted in red. The midline indicates the median value, and the box shows the first and third quartile. Error bars indicate the SD. ***p-value* <0.001 (Mann-Whitney test). **d**. Bar plot showing the steady-state *ZAM* RNA levels in total RNA from ovaries with the indicated genotypes (RT-qPCR, normalized to *rp49*, primer sequences in Supplementary Table S5). At least three biological replicates and two technical replicates were used. **p-value* <0.01 (Mann-Whitney tst); error bars indicate the SD. **e**. Scatter plot showing the normalized counts of antisense Piwi-bound piRNAs mapping to individual internal TE sequence in control ovaries (*white*-sKD) versus *yb*-sKD ovaries. Antisense piRNA counts, mapped allowing up to 3 mismatches, were normalized per million of genome-mapping piRNAs (RPM, here in logarithmic scale). TEs in blue have a *yb*-sKD/*white*-sKD ratio >3; TEs in red have a ratio <0.3. *ZAM* is boxed in black. **f.** Density plot along the *ZAM* sequence of *ZAM*-mapping regulatory piRNAs produced in *white*- and *vret*-sKD ovaries (up to 3 mismatches). **g**. Fold-change in the steady-state *ZAM, Gypsy* and *Burdock* RNA level for the indicated sKD ovaries, compared with *white*-sKD ovaries, measured by RT-qPCR (primer sequences in Supplementary Table S5). At least three biological replicates and two technical replicates were used. **p-value* <0.01 (Mann-Whitney test); error bars indicate the SD. **h**. Color-inverted confocal images of ovarioles (upper panels) and stage 10 egg chambers (lower panels) from the indicated sKD lines showing *ZAM* RNA expression in follicle cells and in the ooplasm in indicated conditions.

1055
1056
Supplementary Figure 3 (related to Figure 3):
a. Color-inverted confocal images of early embryos collected 0-2 hours after egg laying (AEL).
Mothers harbor the indicated sKD of the piRNA pathway. *ZAM* RNA signal was detected by
smRNA FISH. **b.** Projection of confocal images of stage 1 embryos (0-1 h AEL) laid by *vret*-
sKD females showing *ZAM* RNA detected by smRNA FISH and Aub protein immunostaining.
Both accumulated at the posterior pole of the embryo where future germ cells cellularize (Z-
projection of 25 stacks).
1064
1065

1066

1067
1068

Supplementary Figure 4 (related to Figure 4):
a. Sequence alignment of the RevI-H2 consensus *ZAM* LTR and the *ZAM* solo-LTR that
remains in the *flamΔZAM* line after CRISPR-Cas9 deletion of the internal *ZAM* sequence in
flamenco. The image shows the RevI-H2 consensus *ZAM* LTR (upper sequence) and the *ZAM*
solo-LTR (lower sequence) with their TATA-box and polyadenylation signal (pA-signal) at
position 312 of the *ZAM* consensus, the transcription start site (TSS, at position 327), the start
of the poly-A tail at position 341 (CAAGCAGC-(A)n), according to Leblanc et al, 1997. **b.** RT-
PCR results showing the expression of the different *ZAM*-variants in the ovaries of the
following fly lines: *flamΔZAM*, RevI-H2i2 and *flamΔ*ZAM with three copies of *ZAM* from the
RevI-H2 X chromosome (one *ZAM-fl*, one *ZAM-v2* and one *ZAM-v3*). Three biological
replicates were used for each condition (s1, s2, s3). *Rp49* has been used as the housekeeping
gene control. The primers used for specific amplification of each variant are indicated on the

schematic representation of *ZAM* variants and represented by arrows, and color-coded as follows: Blue: Primers for specific amplification of *ZAM-fl*. Orange: Primers for specific amplification of *ZAM*-v2 (primer *ZAM*-v2_R overlaps left and right edges of the *ZAM*-v2 deletion). Yellow: Primers for amplification of Z*AM-fl* and *ZAM*-v3, where the size of the amplification product differs due to a specific deletion in the 5'-UTR of *ZAM*-v3. (primer sequences in Supplementary Table S5).

Supplementary Figure 5 (Related to Figure 5)

a. Density plot of *ZAM*-mapping regulatory piRNAs (23-29 nt small-RNAs complexed with Argonaute proteins) along the *ZAM* internal sequence in *flamΔZAM*-RevI-H2i2 chr II ovaries (up to 3 mismatches). **b.** Scatter plots showing the normalized counts of regulatory piRNAs mapping to individual internal TE sequences in control ovaries (*white*-sKD) versus *flamΔZAM*-RevI-H2i2 chr II ovaries. Antisense piRNA counts, mapped allowing up to 3 mismatches, were normalized per million of genome-mapping piRNAs (RPM, here in logarithmic scale). **(c)** Density plot of total small RNAs of 23 to 29 nt along the *ZAM* sequence in *white*-sKD, *vret*-sKD and *yb*-sKD ovaries (up to 3 mismatches). **c.** Density plot of total *ZAM*-mapping small RNAs of 23 to 29 nt along the *ZAM* internal sequence in *white*-sKD, *vret*-sKD and *yb*-sKD ovaries (up to 3 mismatches). **d**. Sequence logo for the first ten positions in ZAM-mapping sense small RNAs of 23 to 29nt (from total ovarian small RNA) in *vret*-sKD ovaries. The nucleotide height represents its relative frequency at that position. **e.** Density plot of *ZAM*-mapping Piwi-bound piRNAs along the *ZAM* internal sequence in *white*-sKD, *vret*-sKD and *yb*-sKD ovaries (up to 3 mismatches). **f.** Density plot of *ZAM*-mapping regulatory siRNAs (21nt small-RNAs complexed with Argonaute proteins) along the *ZAM* internal sequence produced in *white*-sKD and *vret*-sKD ovaries (0-1 mismatch).

1108

1109

* shRNA of RNAi located on the chromosome III = *white*-sh (BDSC_35573) , *vret*-sh (VDRC_34897) , *armi*-sh (BDSC_34789) , *zuc*-sh (BDSC_35227), *Ago3*-sh (BDSC_35232)

* shRNA of RNAi located on the chromosome II = *piwi*-sh (BDSC_37483)

M* = PBac{w[+mC]=PB}CG11583[c01124] P{ry[+t7.2]=neoFRT}80B
FM7a = Bar[1] sc[8] v[Of] w[a] y[31d]
Pin = βTub60D[Pin-1]

1110

1111 **Supplementary Figure 6**

1112 Description of the genetic crosses performed to obtain the different RevI-H2i2-GLKD lines.

1113

1114

1115

1116

1117 **Supplementary Video 1**

1118 Video of confocal Z-stacks overlay of stage 10 egg chambers from vret-sKD ovaries expressing

1119 Yolk-protein-1-GFP (green) showing ZAM smRNA FISH signal (red).

1120

1121

Supplementary Table S1 – ZAM insertions in the RevI-H2i2 genome

number	chromosome	insertion site (Release 6 genome)	orientation	type	locus	comment
1	X	X:1602129-1602133	minus	ZAM-v2	intron of the overlapping Mur-2B and broad genes	ZAM deleted for internal positions 5494-6120 (Repbase ZAM_I)
2	X	X:1980714-1980717	minus	ZAM-fl (full-length)	intron of gene Hr4	
3	X	X:19249375-19249375	minus	ZAM-v3	intron of gene Hs3st-B	ZAM deleted within the 5'-UTR, internal positions 645-951 (Repbase ZAM_I), inserted in a Jockey TE which is absent in the reference genome
4	X	X:22257753 or X:22373661	minus	ZAM-fl (full-length)	piRNA cluster 56 or 13 (George, Jensen et al., 2015)	
5	X	X:23212829	plus	ZAM-fl (full-length)	piRNA cluster 9 (X:23150001-23545000, George, Jensen et al., 2015)	
6	X	X:23368838-23368841	minus	ZAM-v2	piRNA cluster 9 (X:23150001-23545000, George, Jensen et al., 2015)	ZAM deleted for internal positions 5494-6120 (Repbase ZAM_I)
7	X	X:23513106-23513113	minus	ZAM-v2	piRNA cluster 9 (X:23150001-23545000, George, Jensen et al., 2015)	ZAM deleted for internal positions 5494-6120 (Repbase ZAM_I)
8	2L	2L:8158963-8158966	plus	ZAM-fl (full-length)	intron of gene PAPLA1	inserted in a NOMAD TE which is absent in the reference genome
9	2L	2L:15773891-15773894	plus	ZAM-fl (full-length)	intergenic region	
10	2R	2R:1808663-1817084	plus	ZAM-fl (full-length)	intergenic region	ZAM copy also present in the reference genome Release 6
11	2R	2R:6793620-6793623	plus	ZAM with an internal deletion	intron of gene Epac	ZAM deleted for internal positions 2332-5754 (Repbase ZAM_I)
12	2R	2R:11601808-11601811	plus	ZAM-v3	intron of gene toutatis	
13	3L	3L:4299131-4299137	minus	ZAM-v1	intron of gene dyl	ZAM deleted for the 5'-UTR, internal positions 60-1218 (Repbase ZAM_I)
14	3L	3L:19980882-19980883	minus	ZAM with internal deletions	intergenic region	ZAM deleted for internal positions 13-2993 and 5494-6120 (Repbase ZAM_I)
15	3R	3R:12079947-12079950	plus	ZAM-v2	intron of gene ATP8B	ZAM deleted for internal positions 5494-6120 (Repbase ZAM_I)
16	unknown	NW_007931121.1:45136-45142	plus	ZAM-fl (full-length)	rDNA	
17	unknown	possibly close to X:23239427	(plus)	ZAM with internal deletions	possibly piRNA cluster 9 (X:23150001-23545000, George, Jensen et al., 2015)	ZAM deleted for internal positions 2332-5754 and 6116-7265 (Repbase ZAM_I)
18	unknown	NW_001845412.1:1075-1078	minus	ZAM with an internal deletion	unknown	ZAM deleted for internal positions 2929-5615 (Repbase ZAM_I)

1122

1123

Supplementary Table 2 – Drosophila lines used

Category	Gene name	CG_Number	Stock number	Genotype	Source	Notes
RNAi line	white	CG2759	BDSC_35573	y[1] sc[*] v[1] sev[21]; P{y[+t7.7] v[+t1.8]=TRiP.GL00094}attP2	Bloomington	
RNAi line	armitage	CG11513	BDSC_34789	y[1] sc[*] v[1] sev[21]; P{y[+t7.7] v[+t1.8]=TRiP.HMS00098}attP2	Bloomington	
RNAi line	yb	CG6272	VDRC_110056	P{KK105851}VIE-260B	VDRC	
RNAi line	piwi	CG6122	BDSC_37483	y[1] sc[*] v[1] sev[21]; P{y[+t7.7] v[+t1.8]=TRiP.GL00626}attP40	Bloomington	
RNAi line	vreteno	CG4771	VDRC_34897	w1118; P{GD11424}v34897	VDRC	
RNAi line	zucchini	CG12314	BDSC_35227	y[1] sc[*] v[1] sev[21]; P{y[+t7.7] v[+t1.8]=TRiP.GL00111}attP2	Bloomington	
RNAi line	argonaute 3	CG40300		y[1] sc[*] v[1] sev[21]; P{y[+t7.7] v[+t1.8]=TRiP.GL00117}attP2	Bloomington	
RNAi line	aubergine	CG6137	BDSC_35201	y[1] sc[*] v[1] sev[21]; P{y[+t7.7] v[+t1.8]=TRiP.GL00076}attP2	Bloomington	
white mutant, otherwise wild-type	white		BDSC_3605	w[1118]	Bloomington	
nanos-Gal4 driver			BDSC_4937	w[1118]; P{w[+mC]=GAL4::VP16-nos.UTR}CG6325[MVD1]	Bloomington	
traffic-jam-Gal4 driver				w; tj-Gal4/CyO	Unknown	
RevI-H2iI					Produced in the lab	Isogenic line derived from the RevI-H2 stock
RevI-H2i2					Produced in the lab	Isogenic line derived from the RevI-H2 stock
RevI-H2i3					Produced in the lab	Isogenic line derived from the RevI-H2 stock
RevI-H2i4					Produced in the lab	Isogenic line derived from the RevI-H2 stock

1124

1125

1126

1127

Supplementary Table 3 – smRNA FISH probes		
Oligo number	**ZAM (this paper) 5'- 3'**	**Burdock (from Senti and al,.2015) 5' - 3'**
1	GAAAAAGAAATGTTGGCAAT	AGGTTATCACTGTCACTCAT
2	AATATGGGCAGTAAAATACT	GCTTGACACTAGGTTGTCTA
3	AGACCATATATTTATGGCGT	TGGTGCGCTGACCATTTATT
4	TACAGATCACAAGCCACTAA	TTTTTTCTGCACTGTTTTGC
5	TGAATTTCAAAGAACCCAAC	CCACCAATTATCTGATGACT
6	AAAAATAATTCGTTGGGAGAC	CGCTAGTTGTCTTTGTTTTT
7	TCCAACTCATGGAATACAAT	AACTGAGCTTCAAATTCCAT
8	TCACAAGAAAGGTTCACAAA	AACAGCACTCTCTACGATCG
9	TGTAATTGCAGACGCCTTAA	TGATTGTTTTTGGACTGCGA
10	GTAGAGCGGACCCAAATTTA	TCATTCATCTCCTGCAATTG
11	AACTACAACGAAACACTGAC	GGTGTTCACTGTTAATTTCC
12	TGTTAAGCCTTGCCCCACAT	CTACATAAGTTTCCACCTCT
13	CCGAAAAACCTATTAACGAA	TATATCTAGAGGCTCGCTAC
14	AACACGCAACTCATACTAGA	GCCATCAAAATCTGGCAGAG
15	TCTTACCAAACTACAACACC	CTTCCCTCGTAATCTTTGAA
16	AGGAAAAAATATTCACAGCC	CCAAGAGCTTGGTAAAATGT
17	AAAATCTTGAAAGGAACCCT	AAGCCAATACTGTATTCGCT
18	AAAACCTAACAGGATTTGCG	GCTTTGAAATGTAACGGAGT
19	CATTCTTGGCGGACGATAAT	TGTGAAATCAAGACGGCTGA
20	TCCGCATTAATCGAAAAAGC	TAGATAGATCGGCCTTTTGT
21	TTCTCCACGAAATCGTAGGA	GTCGCAAAGTTGATAGCTCT
22	ACCCCGAACAAAACAAATTC	TCAGTAAGAGTCATGTCTCC
23	GGAATATCACACTAACAGCA	TCTTGTTGGTAAGTAGGGTC
24	GAGGCATAGACGAAACATTC	GCCAAGGCACTATCAAATGT
25	TTCACCTCAAACGAGAAACC	GTCCTGTACTTTTCATTCAG
26	ACTTCCCCAATATGAAAAAC	CTCCGGTTACAAATACACGT
27	AATTAGGAATTGCGAAACCT	ATGTCGCTCAACGATTTCTT
28	GTCTAAAACTCAAATACGAC	ATCTTTTGGACCTTTTGCAA
29	AGGCAACCACAAAATATAGT	TGGTTCGACTCGACCTCTTG
30	ATTTGAAACCCCAGAAACCC	AAGGGCGAATTGGTAACGCT
31	GAAACCCCTCGACATAATAC	CCCTGTCTCCAATATTTTTA
32	ACCTGACAATCATAGACAAA	TGCCTTTGTTCGATTTTCTG
33	TCTCAAAATTCGCAGCTGTC	TGAGTTTCTATCCTTATCGC
34	TACCCCATCCCAAATAGAAA	TTTTTAGTTTGCATGGGCAT
35	CGGCATCAATTGCATCAAAG	CACCTGACGCTTGCTAAAAT
36	TTCAGTCAATTCGGACTACC	GGATTTGTTAACTGGACTGG
37	CAAAAAACTAATACACGACC	TTCTTCTAGATCGCATGGAT
38	AGGAGTAGAATTTTGCAACG	GGAGTTTGTCCAAAATTTCC
39	CCATGTCACATCCTTCCAGC	AATATTTCCCTGAGTCGGAA
40	AGTAATTCTCCAGTAGAACG	GGTTGCGATGCGAATTGATT
41	ACACTCCTCTTTGACAGAGA	CTGACTTGTGTTTTGCTGTT
42	AATACTAGACACACGGAAAA	TTGCGCATACCCAAAATGTC
43	ACACAAATTACCTACAGACC	CACTCGTTGGTCTTTTTGAT
44	ACGAAGAAATAATGTCAGAA	TTTTGGCCCTGTAAACCTTG
45	ATAACAACGCAATCCACTCC	GGTAAGTAGTTGATCCTCTG
46	CCACCAAACACACCCCTTTT	CTCACATTGACCTTTCTCAT
47	TGGTAGGACCCATTTATTCG	CCTTTTGATAACCGTCTGTA
48	ATACCCAATAATGAGCATGA	ATAATCATCAACCTCCGCTT

1128
1129
1130
1131

Supplementary Table 4 – Antibodies used					
Antibody	**Source**	**Dilution**	**Fluorochrome**	**Species**	**Reference**
Primary antibody					
Goat anti-GFP	abcam	1/1000		Goat	ab5450
Rabbit anti-Aubergine	Homemade (Eurogentec) - polyclonal antibody	1/1000		Rabbit	
Rabbit anti-Gag-ZAM	Homemade	1/100		Rabbit	
Rabbit anti Env-ZAM	Homemade	1/1000		Rabit	
Secondary antibody					
Alexa Fluor 488 donkey anti-goat IgG (H+L)	Invitrogen (Fisher)	1/1000	Alexa 488	goat	A11055
Donkey anti-rabbit Alexa 488 IgG (H+L) 2mg/ml	life tech	1/1000	Alexa 488	rabbit	A21206
Goat anti-rat Cy3	Jackson Immunoresearch	1/1000	Cy3	rat	112-165-143
Fluorescent dyes					
DAPI	Sigma	1/500			D8417-1MG

1132
1133

Supplementary Table S5 - Primers used

	Name	Sequence	Used for
Rp49	rp49_R	AAACGCGGTTCTGCATGAG	RT-qPCR
	rp49_F	GACGCTTCAAGGGACAGTATCTG	
Burdock	Burdock_F	GGACAAACTCCATTTCCGACTC	RT-qPCR
	Burdock_R	TCCCTGAGCCTGACTTGTGT	
Gypsy	Gypsy-F	CGCTCGAAGGTTACCAGGTAGGTTC	RT-qPCR
	Gypsy_R	CTTCACGTTCTGCGAGCGGTCT	
ZAM	Zam_env_F	CTCCCAATCATCTCCTCCAA	RT-qPCR
	Zam_env_R	AGAAGTCGGGGTGCTCTTCT	
flamenco ZAM	ZAM-FLAM_F	TCGCTTAGGAGGGTAGCTTG	CRISPR SCREEN
	ZAM-FLAM_R	CTTAACACCTACTGTCAGTGC	
ZAM-fl	662_ZAMflRev_6360_F	CCTGCATTCCAGATCTTGCC	RT-PCR
	663_ZAMflRev_6587_R	ATTGATATAGAATCGGTGAGTG	
ZAM-v2	666_ZAMv2Rev_5752_F	GAATTTTGCAACGACATATTTCGA	RT-PCR
	667_ZAMv2Rev_5988_R	AGCATTTAGTATTGATATAGTATTACAG	
ZAM-fl + ZAM-v3	668_ZAMflRev_697_F	TAACCGCGAAACATGATATGC	RT-PCR
	669_ZAMflRev_1835_R	GTGTGTGATTCTAACACGGAG	

1134
1135
1136

Supplementary Table S6 – small-RNA seq

Small RNA seq
TrapR sRNA from RevI-H2i1
TrapR sRNA from RevI-H2i2
TrapR sRNA from RevI-H2i3
TrapR sRNA from RevI-H2i4
Total RNA from RevI-H2i2- nos-Gal4- driven dsRNA-white
Total RNA from RevI-H2i2- nos-Gal4- driven dsRNA-Ago3
Total RNA from RevI-H2i2- nos-Gal4- driven dsRNA-Piwi
TrapR sRNA- from RevI-H2i2- nos-Gal4- driven dsRNA-Zuc
TrapR sRNA- from RevI-H2i2- nos-Gal4- driven dsRNA-white
TrapR sRNA from tj-Gal4-driven dsRNA-Vret
TrapR sRNA from tj-Gal4-driven dsRNA-white
TrapR sRNA from CRISPR flamΔZAM
Total RNA from tj-Gal4-driven dsRNA-Vret
Total RNA from tj-Gal4-driven dsRNA-white
Total RNA from tj-Gal4-driven dsRNA-yb

1137
1138